Anti-JAM-A Antibody, clone 2E9 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 2E9 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects Junctional adhesion molecule A (JAM-A). It targets an epitope within 19 amino acids from the N-terminal, extracellular domain.
• Immunogen: KLH-conjugated linear peptide corresponding to 19 amino acids from the N-terminal, extracellular domain of human Junctional adhesion molecule A (JAM-A).
• Application: Quality Control TestingEvaluated by Western Blotting in MCF-7 cell lysate.Western Blotting Analysis: A 1:10,000 dilution of this antibody detected JAM-A in MCF-7 cell lysate.Tested applicationsWestern Blotting Analysis: A 1:10,000 dilution from a representative lot detected JAM-A in CaCo2 cell lysate and 1:1,000 dilution in HepG2 and HeLa cell lysates.Affinity Binding Assay:: A representative lot of this antibody bound JAM-A peptide with a KD of 1.2 x 10-6 in an affinity binding assay.Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected JAM-A in human liver tissue sections.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end userEvaluated by Western Blotting in MCF-7 cell lysate.Western Blotting Analysis: A 1:10,000 dilution of this antibody detected JAM-A in MCF-7 cell lysate.
• Target description: Junctional adhesion molecule A (UniProt: Q9Y624; also known as JAM-A, Junctional adhesion molecule 1, JAM-1, Platelet F11 receptor, Platelet adhesion molecule 1, PAM-1, CD321) is encoded by the F11R (also known as JAM1, JCAM) gene (Gene ID: 50848) in human. JAM-A is a single-pass type I membrane protein that is localized at tight junctions of both epithelial and endothelial cells. It is also expressed in circulating platelets and leukocytes. It is synthesized with a signal peptide (aa 1-27), which is subsequently cleaved off to produce the mature form that contains an extracellular domain (aa 28-238), a transmembrane domain (aa 239-259), and a cytoplasmic domain (aa 260-299). The extracellular domain contains a membrane distal VH-type Ig-like domain (D1; aa 28-125) and a membrane proximal C2-type Ig-like domain (D2; aa 135-228) that contains a single glycosylation site (Asn 185). The cytoplasmic domain includes two phosphorylation sites (Tyr 280 and Ser 284) and also has a type II PDZ domain-binding motif (aa 297-299). JAM-A plays a role in epithelial tight junction formation and also regulates monocyte transmigration involved in integrity of epithelial barrier. It participates in the regulation of various biological processes, including paracellular permeability, tight junction formation and maintenance, leukocyte trans-endothelial migration, epithelial-to-mesenchymal transition (EMT), angiogenesis, reovirus binding, and platelet activation. Its dysregulation may contribute to pathological consequences, such as cardiovascular diseases, inflammatory bowel disease, neurological disorders, and various cancer types. In cancer cells, it is not only associated with regulation of cell migration, but it also affects apoptosis, EMT, cancer stem cell maintenance, and cell proliferation. Down-regulation of JAM-A results in elevated cell migration, invasion, and metastasis in various breast cancer cell lines. Its higher levels have been linked to reduced cell migration ability of cancer cells. This ZooMAbZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Czubak-Prowizor, K., et al. (2022). Mol. Cell. Biochem. 477(1); 79-98; Liu, X., et al. (2020). Nature. 586(7827); 101-107).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.